Clinical Trial Update: Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria [Phase 3]

View source ↗

Summary

Phase 3 trial update on sirolimus-based immunosuppression after orthotopic liver transplantation for hepatocellular carcinoma exceeding Milan criteria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN